InMode
INMD
About: InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Employees: 599
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]
6.55% less ownership
Funds ownership: 63.28% [Q1] → 56.72% (-6.55%) [Q2]
12% less funds holding
Funds holding: 243 [Q1] → 214 (-29) [Q2]
24% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 83
34% less capital invested
Capital invested by funds: $782M [Q1] → $518M (-$264M) [Q2]
39% less call options, than puts
Call options by funds: $7.79M | Put options by funds: $12.8M
42% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 60
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Barclays
Matt Miksic
|
40%
upside
$21
|
Overweight
Maintained
|
30 Jul 2025 |
|
Canaccord Genuity
Caitlin Cronin
|
0%
upside
$15
|
Hold
Maintained
|
11 Jul 2025 |
Financial journalist opinion
